Join us Friday, December 8th from 8-11pm for Myriad Genetic Laboratories’

LOCATION: Landry’s Seafood House – 3rd floor
517 N. Presa St.
San Antonio, TX 78205

Food and drinks will be served!


We are excited to highlight below studies related to myRisk Hereditary Cancer and EndoPredict:

Poster Discussion PD1-08 // Wednesday, December 6th from 5:00pm-7:00pm

Development and Validation of a Combined Residual Risk Score to Predict Breast Cancer Risk in Unaffected Women Negative for Mutations on a Multi-Gene Hereditary Cancer Panel

Presented by: Elisha Hughes, PhD, Myriad Genetic Laboratories


Poster Discussion P3-08-01 // Thursday, December 7th from 5:00pm-7:00pm

Prognostic performance of EndoPredict in invasive lobular carcinoma

Presented by: Ivana Sestak, Ms, PhD, Queen Mary, University of London | QMUL · Wolfson Institute of Preventive Medicine


General Session 6 GS6-04 // Friday, December 8th at 4:00pm

The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrine therapy in HR+/HER2- breast cancer patients from ABCSG 34.

Presented by: Peter Dubsky, MD, Medical University of Vienna and Breast Center Klinik St. Anna, Lucerne

Myriad is a proud supporter of the following Research to Practice CME event:

Tuesday, December 5, 2017, 8:00 PM – 9:45 PM
at the San Antonio Marriott Rivercenter

Data + Perspectives: Clinical Investigators Explore the Emerging Role of PARP Inhibition in the Management of Breast Cancer

Learn more and register online at:

Leave a Reply

Your email address will not be published. Required fields are marked *